Applied Filters
Swiss pharma company reveals SCOTUS appeal plans
Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.
Big pharma firm settles HIV drug disputes with generic makers
Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.
Generic maker urges review of $235m skinny label decision
A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.
Novartis sued over blockbuster heart failure drug
Pharma company facing lawsuit from two universities | Dispute centres on therapeutically effective co-crystals patent.
Gilead must face pay-for-delay suit
Class-action alleges pharma company blocked rival HIV drug | Health insurance trust convinces judge a reverse payment may have been made.
Chugai settles cancer drug patent dispute with US firm
Parties to withdraw lawsuit over lung cancer drug | ANDA generic would have displaced sales of patented version in Delaware, said plaintiff.
Pharma unit could get green light to launch IBS generic
Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.
ViiV Healthcare signs deal to boost HIV drug access
Pharma firm joins with patent pool to expand access to HIV treatment | 90 countries set to benefit from preventative medicine
Competition watchdog fines big pharma duo £70m
The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.
Generic maker pays $145m to settle antitrust suit
California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.
